Format

Send to

Choose Destination
Am J Transplant. 2019 Aug 25. doi: 10.1111/ajt.15579. [Epub ahead of print]

The use of ruxolitinib for acute graft-versus-host disease developing after solid organ transplantation.

Author information

1
Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri.
2
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri.

Abstract

Development of graft-versus-host disease (GvHD) is a rare complication after transfusions or solid organ transplantation. Patients typically present with a skin rash, diarrhea, liver failure, and bone marrow aplasia. A diagnosis of transfusion/transplantation associated-GvHD is made based on the clinical and histologic evidence, yet it is often delayed due to the nonspecific symptoms attributed to the patient's underlying illness. Several therapeutic approaches are being used including both increasing and withdrawing immunosuppression, and the use of cellular therapies. Unfortunately, the success rate of these approaches is low and the mortality of this complication is very high. New approaches are needed. We report on three cases of GvHD developing after solid organ transplantation treated with ruxolitinib.

KEYWORDS:

clinical research/practice; graft-versus-host disease (GVHD); hematology/oncology; immunosuppressant - other; immunosuppression/immune modulation; organ transplantation in general

PMID:
31446673
DOI:
10.1111/ajt.15579

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center